Recently, several lines of evidence showed that 1,25-dihydroxyvitamin D (1,25(OH)2D), whose action is mediated through binding to the Vitamin D receptor (VDR) and is the active metabolite of vitamin D, could reduce the risk of RCC [4–7]. This evidence concerns the gene VDR and renal cell carcinoma.